<DOC>
	<DOCNO>NCT01893190</DOCNO>
	<brief_summary>Phase 1/2a Multicenter , Controlled , Randomized , Open Label , Dose Escalation , Safety , Tolerability , Pharmacokinetic Study Comparing EG-1962 Nimodipine Patients Aneurysmal Subarachnoid Hemorrhage</brief_summary>
	<brief_title>Safety Tolerability Study EG-1962 Aneurysmal Subarachnoid Hemorrhage</brief_title>
	<detailed_description>This Phase 1/2a multicenter , control , open label , randomize , study . Part 1 study single dose escalation period determine MTD EG-1962 . During period , maximum 6 dose level cohort 12 patient per cohort enrol . In cohort , patient randomly assign ratio 3:1 receive either intraventricular EG 1962 enteral nimodipine , respectively . The first cohort receive 100 mg EG 1962 . Upon completion dose escalation period , safe tolerable dose select study . Part 2 study treatment period ass safety tolerability select dose EG-1962 . The safety tolerability single intraventricular dose EG 1962 compare enteral nimodipine ( 60 mg give every 4 hour orally via nasogastric gastrostomy tube ) 21 day .</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Rupture</mesh_term>
	<mesh_term>Intracranial Aneurysm</mesh_term>
	<mesh_term>Nimodipine</mesh_term>
	<criteria>Male female age 18 75 year , inclusive ; WFNS Grade 2 , 3 , 4 assess treatment aneurysm prior administration EG1962 ; Ruptured saccular aneurysm confirm angiography ( catheter CTA ) treat neurosurgical clipping endovascular coiling ; Subarachnoid hemorrhage baseline CT scan diffuse ( clot present hemisphere ) thick ( &gt; 4 mm ) thin , local thick ; External ventricular drain ( EVD ) place ; The patient able receive EG1962 within 60 hour onset subarachnoid hemorrhage ( SAH ) . Onset SAH define time patient experience first symptom SAH ( e.g. , severe headache loss consciousness report either patient witness ) . If find unconscious , onset SAH define last time patient see baseline neurological state ; Weight &gt; 45 kg ; Hemodynamically stable resuscitation systolic blood pressure ( SBP ) ≥90 mm Hg without use inotropic agent ; Signed informed consent patient patient 's legal representative completion aneurysm repair study criterion confirm ; Female patient child bear potential must negative pregnancy test . Male patient must agree use adequate birth control study 1 month discontinuation study drug treatment . Subarachnoid hemorrhage due cause saccular aneurysm ( e.g. , trauma rupture fusiform infective aneurysm ) ; WFNS Grade 1 5 assessed completion aneurysm repair prior administration EG1962 ; Increased intracranial pressure &gt; 30 mm Hg sedate patient last &gt; 4 hour anytime since admission ; Intraventricular intracerebral hemorrhage absence SAH local , thin SAH ; Angiographic vasospasm prior aneurysm repair procedure , document catheter angiogram CT angiogram ; Major complication aneurysm repair , limited , massive intraoperative hemorrhage , brain swelling , arterial occlusion , inability secure rupture aneurysm ; Aneurysm repair require flow divert stent stentassisted coil dual antiplatelet therapy ; Hemodynamically unstable prior administration study drug ( i.e. , SBP &lt; 90 mm Hg , require &gt; 6 L colloid , crystalloid fluid resuscitation ; Cardiopulmonary resuscitation require following SAH ; Female patient positive pregnancy test ( blood urine ) screening ; History within past 6 month and/or physical find admission decompensated heart failure ( New York Heart Association Class III IV heart failure require hospitalization ) ; Acute myocardial infarction within 3 month prior administration study drug ; Symptoms electrocardiogram ( ECG ) base sign acute myocardial infarction unstable angina pectoris admission ; Electrocardiogram evidence and/or physical finding compatible second third degree heart block cardiac arrhythmia associate hemodynamic instability ; Echocardiogram , perform part standardofcare treatment , reveal leave ventricular ejection fraction &lt; 40 % ; Severe unstable concomitant condition disease ( e.g. , know significant neurologic deficit , cancer , hematologic , coronary disease ) , chronic condition ( e.g. , psychiatric disorder ) , , opinion Investigator , may increase risk associate study participation study drug administration , may interfere interpretation study result ; Patients receive investigational product participate another interventional clinical study within 30 day prior randomization . Patients participate noninterventional study bear assessment EG1962 enteral nimodipine enrol per guideline local Institutional Review Board ( IRB ) / independent Ethics Committee ( IEC ) . Kidney disease define plasma creatinine ≥2.5 mg/dl ( 221 μmol/l ) ; liver disease define total bilirubin &gt; 3 mg/dl ( 51.3 μmol/l ) ; and/or know diagnosis clinical suspicion liver cirrhosis ; Known hypersensitivity nimodipine dihydropyridine calcium channel antagonist , polyD , Llactidecoglycolide ( PLGA ) , hyaluronic acid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Ruptured saccular aneurysm</keyword>
	<keyword>nimodipine</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>Subarachnoid hemorrhage</keyword>
</DOC>